Infliximab: a novel treatment option for refractory orofacial granulomatosis.
Peitsch
Wiebke K
WK
Kemmler
Nicole
N
Goerdt
Sergij
S
Goebeler
Matthias
M
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D051261:Granulomatosis, Orofacial / Q000188:drug therapy*; D006801:Humans; D000069285:Infliximab; D008297:Male
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000069285:Infliximab